• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cellular Physiology and Biochemistry >HIF1α Genetic Variants and Protein Expressions Determine the Response to Platinum Based Chemotherapy and Clinical Outcome in Patients with Advanced NSCLC
【24h】

HIF1α Genetic Variants and Protein Expressions Determine the Response to Platinum Based Chemotherapy and Clinical Outcome in Patients with Advanced NSCLC

机译：HIF1α遗传变异和蛋白质表达确定晚期NSCLC患者对铂类化学疗法的反应和临床结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

biAim /i/bTo investigate whether the hypoxia-inducible factor-1α (HIF-1α) genetic variants and protein expression affect the chemotherapy response and the clinical outcome of patients with advanced non-small cell lung cancer (NSCLC). biMethods /i/bA total of 741 patients with histologically confirmed advanced NSCLC were recruited. Two polymorphisms of HIF-1α gene, namely, the C1772T (P582S) and G1790A (A588T) polymorphisms were determined. The HIF-1α protein expression was determined in 162 different biopsy samples by immunohistochemistry. biResults /i/bAll patients received platinum-based chemotherapy, 311 were chemotherapy responders and 430 were non-responders. The 1772 CC genotype carriers had a higher chance to be chemotherapy responders compared with those carrying the TT genotype. Patients with high HIF-1α expressions had a significantly higher chance to be non-responder to chemotherapy than those with low HIF-1α expressions. The patients with 1772CC had markedly longer overall survival (OS) and progression free survival (PFS) than those carrying the 1772CT and 1772TT genotype. The HIF-1α expression level was significantly related to the OS, but not PFS. biConclusion /i/bThe results of our study suggest that HIF1α genetic variants and protein expression may be used as marker to screen NSCLC patients who are more likely to be responder to platinum based chemotherapy.
机译：目标 研究缺氧诱导因子-1α（HIF-1α）基因变异和蛋白表达是否影响晚期非小细胞肺癌的化疗反应和临床结局细胞肺癌（NSCLC）。 方法 总共招募了741例经组织学证实为晚期NSCLC的患者。确定了HIF-1α基因的两个多态性，即C1772T（P582S）和G1790A（A588T）多态性。通过免疫组织化学测定162种不同的活检样品中的HIF-1α蛋白表达。 结果 所有患者均接受了铂类化疗，其中311例为化疗反应者，430例为非反应者。与携带TT基因型的携带者相比，1772 CC基因型携带者更有可能成为化疗反应者。 HIF-1α高表达的患者比HIF-1α低表达的患者对化疗无反应的机会要高得多。与携带1772CT和1772TT基因型的患者相比，拥有1772CC的患者的总生存期（OS）和无进展生存期（PFS）明显更长。 HIF-1α表达水平与OS显着相关，但与PFS无关。 结论 我们的研究结果表明，HIF1α遗传变异和蛋白质表达可以用作筛选NSCLC患者的标志物，这些患者更可能对铂类化疗有反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号